Research and Development Pipeline Watch: The Top 10 Drugs that Johnson and Johnson Has Most Potentialtoed

Johnson and Johnson, one of the world's largest pharmaceutical companies, recently reported third-quarter 2019 sales of $20,729 million, including $10.877 billion in pharmaceutical sales and rapid growth in immunology and oncologyBehind the rapid growth of Johnson and Johnson's pharmaceutical business is a wealth of pipeline stocks, especially in immunology and oncology, with several potential annual sales of billions of dollars in heavy-duty pipeline drugs, while Johnson and Johnson has some breakthroughs in areas where few new drugs have appeared, such as flu and depressionthis article takes stock of The Top 10 Drugs from Johnson and Johnson as of the first three quarters of 2019, in combination with therapeutic effects, innovation and market valueTOP10 Apalutamide
Apalutamide, a nonsteroidal-selected competitive androgen receptor inhibitor acquired by Johnson and Johnson in 2013 for a maximum price of $1 billion, was approved by the U.SFDA in February 2018 for treatment for non-metastatic resistance to prostate cancerApalutamide is Aragon's flag drug, and Johnson and Johnson's acquisition of Aragon is based on the importance of Apalutamide in order to maintain its dominance in the field of prostate cancer drugsthe current best-selling drug, Abiton, faces patent expirations, and Apalutamide can be a powerful complementThere are still several clinical studies under way in Apalutamide, including china, which is undoubtedly good news for Chinese patientsThe same mechanism, Xtandi, costs as much as $129,000 per course and is not yet available in ChinaTOP9 PimodivirPimodivir is a flu-based drug targeting the influenza virus polymerase complex pb2 subunit, a first-in-class drugJohnson and Johnson acquired Pimodivir's global development interest in 2014 from Thebiotpharmaceuticals in Bostonthe key toinfluenza A treatment is how to overcome drug resistance, and Pimodivir can inhibit the influenza virus polymerase compound pb2 subunit, which is a good solution to the problem of drug resistanceThe drug was completed in June 2017 in a clinical Phase IIb study for the treatment of adult patients with seasonal influenza A, and the results were positive: Pimodivir single-drug use significantly reduced the patient's viral load by 7 days compared to the placebo group, while Pimodivir and Oseltamivir were used to reduce the patient's viral load to a lower level with no adverse reactionsPimodivir has been granted fast-track status by the FDA in March 2017 and will begin clinical Phase III research in the second half of 2017 and is expected to be available in 2020 TOP8 Guselkumab
Guselkumab, the world's first anti-IL-23 monosconomic drug, was approved by the U.S FDA on July 13, 2017, for the treatment of moderate to severe plated psoriasis The clinical results published by Johnson and Johnson show that the effect of Guselkumab in treating plaque psoriasis at different doses is significantly better than that of Sumerle (Adamu monoantigen), this alone is not enough to show that this drug will become a heavy bomb-type drug, strong survivors are actively expanding the scope of the drug's indications, currently used in the treatment of psoriasis arthritis, Crohn's disease, children's psoriady and other autoimmune diseases clinical research is under way Guselkumab has done well since going public, with sales of $742 million in the first three quarters of 2019 TOP7 Erdafitinib
Erdafitinib is the FDA-approved first fibroblast growth factor receptor (FGFR) kinase inhibitor, which was accelerated by the U.S FDA in April 2019 to treat adult patients who carry susceptible FGFR3 or FGFR2 genes and receive at least one localized advanced or metastatic bladder epithelial cancer that involves the progressof the disease during or after platinum chemotherapy Erdafitinib was discovered by Astex Pharmaceuticals, which in 2008 concluded an exclusive global licensing and cooperation agreement with Astex to jointly develop and commercialize Erdafitinib At present, Erdafitinib has a number of clinical studies in progress, the industry is very optimistic about the sale prospects of the drug, the annual sales are expected to be no less than $1 billion TOP6 Esketamine unlike listed antidepressants, Esketamine, a new antidepressant, is a non-competitive N-methyl-D amycin receptor antagonist that regulates the plasticity of neurosynaptic synapses between brain cells in patients with glycine receptor activity, improving symptoms quickly and lastingly, while also having the function of dopamine reuptake inhibitors in September 2018, Janssen submitted to the U.S FDA a new application for Esketamine nasal spray for treatment of adult patients with immune depression, and was approved by the FDA in March 2019 Esketamine became the first new drug in nearly 50 years to treat severe depression with incurable conditions Applications for new drugs to market were submitted in the EU in October 2018 and are expected to be approved The drug is also being studied in Phase III clinical studies with severe depression associated with suicide risk, with nearly 300 million people with severe depression worldwide, one-third of whom are not responding to existing treatments and are in urgent need of new drugs to help patients escape the mental illness, so the potential market for Esketamine is huge TOP5 Niraparib Niraparib is an oral highly specific polyadenosine nucleocosin polymerase (PARP) inhibitor that disrupts the PARP-mediated DNA damage repair pathway by inhibiting PARP In tumor cells that carry BRCA1/2 gene mutations or DNA recombination repair mechanisms, PARP inhibitors can cause too much DNA damage that cannot be repaired, killing tumor cells Niraparib was originally developed by TESARO and has been approved for ovarian cancer Johnson and Johnson's Janssen Pharmaceuticals struck a deal with TESARO in 2016 to buy the global development rights for Niraparib Prostate Cancer, an adaptation that cost Johnson and Johnson $335 million in advances, $450 million in mileage and a sales dividend The drug is currently in phase II clinical studies of patients with metastatic resistance to prostate cancer, and in February 2019 Johnson announced preliminary results at the ASCO GU meeting: Niraparib's objective remission rate of about 40% in patients with anti-prostate cancer with mutations in the BRCA1/2 gene Johnson and Johnson has extensive experience in prostate cancer drugs, with zytiga sales of $1.377 billion in the first half of 2019, the world's highest-selling prostate cancer drug, and Johnson and Johnson's acquisition of Niraparib's prostate cancer development rights is a strong combination, the outlook for the drug is more optimistic TOP4 JNJ-68284528 JNJ-68284528, also known as LCARB-38M, was jointly developed by Johnson and Johnson and Nanjing Legends and is currently in the stage of Phase 2 clinical research In May 2019, it was awarded A PRIME certification by the European Medicines Agency (EMA) for the treatment of late-stage recurrent or refractory multiple myeloma JNJ-68284528 is a CAR-T therapy with B-cell mature antigen (BCMA) as its target BCMA is a transmembrane glycoprotein that belongs to the tumor necrosis factor (TNF) receptor superfamily and is widely present on the cell surface of multiple myeloma (MM) CAR-T therapy can specifically identify tumor-related antigens, so that the effect of T cells targeted, killing activity and durability are higher than conventional applications of immune cells, and can overcome the tumor local immunosuppressive microenvironment and break the host immune tolerance state JNJ-68284528 as a hot target and hot method combined with the drug's clinical results and market prospects are worth looking forward to TOP3 Ponesimod
Ponesimod is a selective pyridoxol-1-phosphate receptor 1 (S1P1) regulator for the treatment of recurrent multiple sclerosis (RMS) The drug can functionally inhibit S1P activity and bind lymphocytes to the lymph nodes, reducing the number of circulating lymphocytes, preventing inflammatory immune cells from crossing the blood-brain barrier into the central nervous system (CNS) and damaging myelin this drug is currently in the clinical Phase III study phase, in September 2019 Johnson and Johnson first released ponesimod treatment of recurrent multiple sclerosis adult patients head-to-head PHASE III study OF OPTII, the study compared the efficacy, safety and tolerability of Ponesimod and Aubagio Aubagio is currently an industry-leading oral MS drug, marketed in more than 70 countries worldwide with annual sales of more than $1 billion Clinical trial results show that Ponesimod has shown superiority in both the main and secondary endpoints of the study, while Ponesimod has good safety and tolerance, which proves that Ponesimod is a very promising new drug for multiple sclerosis, which Johnson and Johnson is expected to bring to market next year, although it will encounter significant competitive pressure in March this year, Mayzent, also an S1P-1 regulator, was approved by the U.S FDA, and in June this year, regulatory filings for ozanimod, an oral S1P receptor regulator, from The New Base, were accepted by the FDA and the EUROPEAN Union's EMA It remains to be seen whether Ponesimod will be able to come to the fore TOP2 Ibrutinib
Ibrutinib is an irreversible Bruton tyrosine kinase (BTK) inhibitor commonly used by Johnson and AbbVie, where Johnson and Johnson is responsible for sales outside the United States The drug was first developed by Celera Genomics, a Us., pharmaceutical company, which synthesized a series of small molecules based on chemical structures that inactivate BTK by binding to cysteine-481 covalently near the ATP binding domain, while also irreversibly inhibiting BTK in a targeted combination with cysteine In 2006, Pharmacyclics acquired Ibrutinib from Celera Genomics, and Johnson and Johnson's Pharmaceuticaldivision teamed up with Pharmacyclics to develop it for use in a variety of B-cell malignancies in November 2013 the FDA approved ibrutinib for the treatment of set cell lymphoma, the first approved BTK inhibitor So far, As many as seven indications have been approved for listing in Ibrutinib The drug also has great potential to exploit, and potential indications include a variety of lymphomas such as non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, borderline lymphoma, and first-line treatment of chronic lymphoma leukemia, and dozens of Phase III clinical studies are currently under way the drug's sales in the first three quarters of 2019 exceeded $2.536 billion and will rise sharply as clinical research advances and new indications are approved TOP1 Darzal
Darzalex was approved by the FDA in November 2015 for patients with multiple myeloma who had received at least three treatment options, becoming the world's first monoclonal antibody for CD38 molecules on the surface of tumor plasma cells, which can be induced by a variety of prosthesis-dependent cell toxicity, antibody-dependent cell-mediated cell toxicity and antibody-dependent cell phagocytosis Darzalex has achieved a number of indications in the field of multiple myeloma treatment since its launch in 2015, from the initial four-line therapy to first-line therapy, most recently on September 26, 2019, When Johnson submitted to the FDA Darzalex Joint Standard Care (Botozomi-To-Nadumide, Low-dose Dexamethasone, VTd) first-line treatment suitable for patients with self-directed stem cell (AS) biopsy biotransplant ationoma If successfully, it will strengthen Darzalex's position as a first-line treatment for multiple myeloma Due to the high expression of CD38 in a variety of tumor cells, in addition to multiple myeloma, Daratumumab's potential indications include a variety of blood tumors, lymphoma, as well as non-small cell lung cancer, pancreatic cancer, colorectal cancer, breast cancer, head and neck cancer and other physical tumors, there are several clinical studies in progress Darzalex's sales in the first three quarters of 2019 have reached $2.168 billion, and as its range of indications continues to expand, sales will certainly soar, the market capacity for multiple myeloma is high, with sales of nearly $10 billion a year alone, and Darzalex is likely to be involved in other cancer treatment sand sands, with peak annual sales of more than $10 billion Table 1 A list of the 10 potential drugs : 1 Drug database 2 Johnson and Johnson's official website 3 FDA website